- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03984318
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs (PREMIS)
May 24, 2022 updated by: Gustave Roussy, Cancer Campus, Grand Paris
The prospect of effective immunotherapies for the treatment of patients with cancer is now a clinical reality thanks to the approval of monoclonal antibodies (mAbs) specifically blocking immune checkpoints or ligands such as CTLA-4, PD-1 and PD-L1.
However, these drugs can also induce inflammatory and/or auto-immune complications (Immune-related Adverse Events; IrAE).
IrAE can affect all tissues and sometimes irreversibly.
IrAE may be severe or fatal in the absence of timely and adequate care with anti-inflammatory drugs (steroids) or more specific immunosuppressants.
Thus, IrAE are a new type of toxicities in oncology and represent one of the major limitations for the development of immunotherapy combination therapies.
These IrAE are yet unpredictable.
Indeed, the induction of immunity relies on the host's immune status and it differs from one patient to another and so far nobody has identified the underlying mechanisms responsible for irAE outbreaks.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
1240
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aurélien Marabelle, MD
- Phone Number: +33 (0)1 42 11 42 96
- Email: aurelien.marabelle@gustaveroussy.fr
Study Contact Backup
- Name: Nathalie Chaput, MD
- Phone Number: +33 (0)1 42 11 56 55
- Email: nathalie.chaput@gustaveroussy.fr
Study Locations
-
-
-
Chevilly-Larue, France, 94550
- Recruiting
- Gustave Roussy
-
Contact:
- Meriem MOKDAD-ADI
-
Le Kremlin-Bicêtre, France, 94270
- Not yet recruiting
- Hôpital Bicêtre
-
Contact:
- Olivier LAMBOTTE
-
Le Plessis-Robinson, France, 92350
- Not yet recruiting
- Hopital Marie Lannelongue
-
Contact:
- Jérôme LE PAVEC
-
Villejuif, France, 94800
- Not yet recruiting
- Hopital Paul Brousse
-
Contact:
- Eleonora DE MARTIN
-
-
Val De Marne
-
Villejuif, Val De Marne, France, 94805
- Recruiting
- Gustave Roussy
-
Contact:
- François-Xavier DANLOS, MD
- Phone Number: +33 (0)1 42 11 42 96
- Email: aurelien.marabelle@gustaveroussy.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18
- Patients with either liquid (hematological) or solid malignancy, in any line of treatment.
- Patients treated with an immunotherapy based on immune checkpoint targeted monoclonal antibody (mainly anti-PD-1, anti-PD-L1, anti-CTLA-4 monotherapies and combinations)
- Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
- Patients must be affiliated to a social security system or beneficiary of the same
- Patient able to read and write French
- Women of child bearing potential must have a negative serum or urine β-HCG pregnancy test within 14 days prior to initiation of treatment
- Sexually active women of childbearing potential must agree to use a highly effective method of birth control supplemented by a barrier method during the trial and for the duration planned in the SmPC or the study protocol after the last administration of each immunotherapy
- Sexually active males patients must agree to use condom during the study and for the duration planned in the SmPC or the study protocol after the last administration of each immunotherapy. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception
Exclusion Criteria:
- Patients treated with immunotherapies that do not contain at least one immunomodulatory drug targeted against a co inhibitory checkpoint molecule
- Known severe hypersensitivity reactions to monoclonal antibodies
- Pregnant or breastfeeding women
- Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: patient treated with immune checkpoint targeted monoclonal AB
Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
|
Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Immune-related Adverse Events (irAE)
Time Frame: up to 5 years
|
up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 12, 2018
Primary Completion (Anticipated)
December 11, 2026
Study Completion (Anticipated)
December 11, 2028
Study Registration Dates
First Submitted
June 7, 2019
First Submitted That Met QC Criteria
June 11, 2019
First Posted (Actual)
June 13, 2019
Study Record Updates
Last Update Posted (Actual)
May 27, 2022
Last Update Submitted That Met QC Criteria
May 24, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- 2018-A01257-48
- 2018/2728 (Other Identifier: CSET number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance